Financial Data and Key Metrics Changes - In Q1 2025, the company reported total revenues of $3,400,000, primarily from WICANT, with gross product margins around 88% [16][17] - The GAAP net loss was $9,700,000 or $0.10 per share, a significant improvement from a net loss of $20,300,000 or $0.44 per share in Q1 2024 [17] - Non-GAAP net loss for Q1 2025 was $7,800,000 or $0.08 per share, compared to $17,800,000 or $0.38 per share in the same period last year [17][18] Business Line Data and Key Metrics Changes - WICANT's dispensed applicator units increased by 16.7% over Q4 2024, surpassing 10,000 units for the first time since its launch [6][7] - Collaboration revenues totaled $17,000 in Q1 2025, related to the supply of applicators to Torii Pharmaceutical [16] Market Data and Key Metrics Changes - The company is focusing on territories with high prevalence of molluscum and has established strong insurance coverage, leading to improved sales force productivity [8][9] - The company is expanding its distribution network by adding local independent pharmacies alongside national specialty pharmacy partners [9] Company Strategy and Development Direction - The company is executing a focused commercialization strategy aimed at driving demand for WICANT, which is expected to become the standard of care for molluscum contagiosum [19] - The clinical pipeline includes advancing the phase three program for WICANT in treating common warts and the development of BP315 for basal cell carcinoma [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing positive feedback from healthcare professionals and improved patient access [19] - The company is exploring opportunities to strengthen its balance sheet while advancing commercial and clinical development efforts [18] Other Important Information - The company appointed Dr. Noah Rosenberg as Chief Medical Officer and Dr. Gavin Corcoran to the Board of Directors, enhancing its leadership team [13][14] Q&A Session Summary Question: Discussion on targeting pediatricians and summer demand - Management noted an increasing number of pediatricians prescribing WICANT, with marketing efforts aimed at building awareness for the treatment [22][25] Question: Conversion time between accounts receivable and revenue - The company offers sixty-day payment terms to distributors, expecting stabilization in cash conversion as inventory levels normalize [31][32] Question: Overall TAM for molluscum and coverage split - Management indicated a significant percentage of pediatric patients are covered under Medicaid, while dermatologists have a higher percentage of commercial pay [36] Question: Trends in reordering and applicators per patient - The company is seeing solid growth in customer retention and reordering, indicating positive clinician experiences with the product [42][43]

Product Approval and Launch - YCANTH (VP-102) was approved by the FDA in July 2023 for the treatment of molluscum contagiosum in patients aged two years and older [125]. - The commercial launch of YCANTH (VP-102) occurred in August 2023, supported by a specialized sales team of 35 representatives [126]. - The FDA approved YCANTH (VP-102) for the treatment of molluscum contagiosum on July 21, 2023, with the first commercial sale occurring in August 2023 [165]. Financial Performance - Total revenue for the three months ended March 31, 2025, was $3.4 million, a decrease of 10.1% from $3.8 million in the same period of 2024 [154]. - Product revenue, net increased to $3.4 million for the three months ended March 31, 2025, compared to $3.2 million for the same period in 2024, reflecting a growth of 5.9% [155]. - Collaboration revenue significantly decreased to $17,000 for the three months ended March 31, 2025, from $594,000 in the same period of 2024, a decline of 97.1% [156]. - Total operating expenses decreased to $11.6 million for the three months ended March 31, 2025, down 48.4% from $22.4 million in 2024 [154]. - Net loss narrowed to $9.7 million for the three months ended March 31, 2025, compared to a net loss of $20.3 million in the same period of 2024, an improvement of 52.3% [154]. - Cash and cash equivalents as of March 31, 2025, were $29.6 million, following a net decrease in cash and cash equivalents of $16.7 million during the quarter [165][169]. - Operating activities used $12.7 million of cash during the three months ended March 31, 2025, compared to $19.9 million in the same period of 2024, a reduction of 36.1% [170][171]. Funding and Financial Obligations - The company raised $39.6 million in net proceeds from an underwritten offering of 45,518,243 shares of common stock in November 2024 [133]. - The company is obligated to start making principal payments on a $50 million loan beginning January 1, 2025, due to not meeting specified revenue thresholds [131]. - The Credit Agreement requires the company to maintain a liquidity of at least $10 million and has a waiver for the "going concern" qualification for recent financial statements [132]. - The company anticipates needing substantial additional financing to fund ongoing research and development activities and commercialization efforts [174]. - The company plans to address its going concern issues by obtaining additional funding through equity offerings, debt financing, collaborations, and licensing arrangements [176]. - A milestone payment of $8.0 million is due from Torii upon the first patient dosed in Japan, which may provide additional liquidity in 2025 [176]. - The company relies solely on sales of YCANTH (VP-102) for near-term commercial revenues, with ongoing needs for additional financing [177]. - Future capital requirements will depend on various factors, including clinical trial outcomes and regulatory reviews [178]. - The company may experience dilution of existing stockholders' interests if additional capital is raised through equity or convertible debt securities [179]. - If unable to raise funds, the company may need to delay or terminate product development efforts [180]. Research and Development - The company plans to advance YCANTH (VP-102) for common warts through a global phase three program, potentially starting in mid-2025 [127]. - Research and development expenses are anticipated to increase as the company conducts clinical trials for YCANTH (VP-102) and VP-315 for BCC [148]. - The company is developing VP-315 for the treatment of basal cell carcinoma and expects to report additional data in mid-2025 [129]. Market Risks and Uncertainties - The company faces substantial uncertainty regarding the commercialization of YCANTH (VP-102) and may not achieve necessary data for marketing approval [177]. - As of March 31, 2025, the company had an accumulated deficit of $316.8 million and cash, and cash equivalents of $29.6 million, expected to last until Q3 2025 [175]. - There have been no material changes to the company's disclosures about market risks since the last annual report [182]. - As of March 31, 2025, there have been no material changes to the company's contractual obligations and commitments [181].

Exhibit 99.1 Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – The Company will host a conference call today, May 13 at 4:30 pm, to discuss its first quarter 2025 financial results and provide a business update. To participate in the conference call, please utilize the follow ...

Core Insights - Verrica Pharmaceuticals reported $3.4 million in revenue from YCANTH, driven by a record dispensing of over 10,000 applicator units in Q1 2025, marking a 16.7% increase from Q4 2024 [1][3][8] - The company is advancing its late-stage pipeline, including the completion of an end-of-Phase 2 meeting with the FDA for VP-315, a candidate for basal cell carcinoma, and progressing towards a global Phase 3 program for common warts (VP-102/YCANTH) in collaboration with Torii Pharmaceutical [1][3][9] Financial Performance - For Q1 2025, Verrica recognized product revenue of $3.4 million, with costs of product revenue at $0.4 million, leading to a net loss of $9.7 million or $0.10 per share, compared to a net loss of $20.3 million or $0.44 per share in Q1 2024 [12][20] - Selling, general, and administrative expenses decreased to $8.8 million from $16.3 million year-over-year, primarily due to reduced commercial activity costs [12][20] - Research and development expenses were $2.3 million in Q1 2025, down from $4.9 million in the same period last year, reflecting a decrease in clinical trial expenses for VP-315 [12][20] Business Developments - The company appointed Noah L. Rosenberg, M.D., as Chief Medical Officer, bringing extensive experience in clinical development and product launches [6][7] - Dr. Gavin Corcoran was appointed to the Board of Directors, contributing significant R&D leadership experience [7] Product Insights - YCANTH (VP-102) is the first FDA-approved treatment for molluscum contagiosum, with a strong demand reflected in the dispensing of 10,102 applicator units in Q1 2025 [8][14] - The company plans to provide additional genomic and immune response data for VP-315 in mid-2025, following a positive end-of-Phase 2 meeting with the FDA [9]

Financial Data and Key Metrics Changes - The company reported cash and cash equivalents of $46 million at the end of the previous year [6] - A financing round in November raised $42 million, solidifying the company's balance sheet [7][33] - Cost reductions were implemented, resulting in a decrease of more than half in expenses [10] - The company achieved a quarter-over-quarter growth of 12% in Q4 of the previous year and 16% in Q1 of the current year based on dispensed applicators [11][33] Business Line Data and Key Metrics Changes - The FDA-approved product, Wycanth, targets a market of approximately 6 million patients, predominantly children [5] - The company is expanding its market penetration with additional indications for common warts, potentially reaching an additional 20 million patients [5] - The company has a robust pipeline, including a phase three program for basal cell carcinoma, addressing an additional 3.6 million patients [5] Market Data and Key Metrics Changes - The company has expanded its target population to include pediatricians, in addition to dermatologists, to better address the 6 million target patient population [24] - The covered lives for the product have increased to approximately 225 million as of Q1 [24] Company Strategy and Development Direction - The company is focused on a new commercial strategy for Wycanth, emphasizing HCP-administered products [6] - The management team has been restructured to enhance execution and operational focus [8] - The company aims to drive sales through a tactical sales team that targets pediatricians and primary care practitioners [11][12] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of building brand awareness for Wycanth and the operational efficiency achieved through cost reductions [9][10] - The company is optimistic about its growth trajectory, citing a robust pipeline and minimal cash needs to support ongoing programs [33] Other Important Information - The company has a strong intellectual property portfolio with patents extending into the 1940s [6] - The product Wycanth is the only FDA-approved treatment for molluscum, addressing a significantly underserved patient population [19][18] Q&A Session Summary Question: What feedback is being received from pediatricians regarding treatment versus referrals? - Feedback has been mixed, with a notable increase in pediatricians treating patients directly, especially with the introduction of specialty pharmacy distribution [35][36] Question: Is there a benefit if pediatricians are less willing to treat but still pre-educate parents? - Yes, many pediatricians are now sending patients to dermatologists with a diagnosis, which facilitates quicker treatment [37][38] Question: How far along is the company in specialty pharmacy distribution and reimbursement coverage? - More than half of the business is now through specialty pharmacy, with the sales team effectively addressing insurance plan needs [40] Question: What is the commercial overlap for the common warts indication? - The same call points will be targeted, including primary care, pediatricians, and dermatologists, facilitating a seamless integration into existing relationships [41] Question: What is the competitive landscape for common warts treatment? - Current treatments are limited to liquid nitrogen or curettage, presenting a robust opportunity for the company's product [42] Question: What proportion of physicians are still comfortable with compounded products? - There has been a shift towards acceptance of the FDA-approved product as insurance coverage improves, particularly among younger clinicians [44]

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Events - The company will host a conference call and live webcast on May 13, 2025, at 4:30 p.m. ET to discuss its financial results for Q1 2025 and provide a corporate update [1] - Participants can join the call via telephone or through a live audio webcast available on the company's investor relations website [2]

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Event - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will present at the Citizens Life Sciences Conference in New York City on May 7, 2025, at 3:00 pm ET [1][2] - Participants can access a live webcast of the event through a link provided, with a replay available for 90 days post-event [2]

– Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases req ...

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly a ...

Shares of Verrica Pharmaceuticals Inc. (VRCA) have been struggling lately and have lost 15.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors. Like every technical indicator ...